Chapter 2 Purines

Principles of Medical Biology

Volumn 4, Issue PART 2, 1996, Pages 49-75

  Hoyle, Charles H V ^a   Burnstock, Geoffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957069857     PISSN: 15692582     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-2582(96)80089-4     Document Type: Article

References (208)

1. Abbracchio M.P., Cattabeni F., Fredholm B.B., and Williams M. Purinoceptor nomenclature: A status report. Drug Dev. Res. 28 (1993) 207-213
2. Abbracchio M.P., and Burnstock G. Purinoceptors: Are there families of P2X and P2Y purinoceptors. Pharmacol. Ther. 64 (1994) 445-475
3. Akasu T., Shinnick-Gallagher P., and Gallagher J.P. Adenosine mediates a slow hyperpolarizing synaptic potential in autonomic neurones. Nature 311 (1984) 62-65
4. Andrews T.M., and Holton P. The substance P and adenosinetriphosphate (ATP) contents of sensory nerve on degeneration. J. Physiology 143 (1958) 45-46P
5. Avery R.K., Bleier K.J., and Pasternack M.S. Differences between ATP-mediated cytotoxicity and cell-mediated cytotoxicity. J. Immunology 149 (1992) 1265-1270
6. Barberis C., and McIlwain H. 5′-Adenine nucleotides in synaptosomal preparations from guinea-pig neocortex: Their change on incubation, superfusion and stimulation. J. Neurochem. 26 (1976) 1015-1021
7. Barnard E.A., Burnstock G., and Webb T.E. G-protein-coupled receptors for ATP and other nucleotides: A new receptor family. Trends Pharmacol. Sci. 15 (1994) 67-70
8. Belhassen B., and Pelleg A. Acute management of paroxysmal supraventricular tachycardia: Verapamil, adenosine triphosphate or adenosine?. Am. J. Cardiology 54 (1984) 225-227
9. Benham C.D. ATP joins the fast lane. Nature 359 (1992) 103-104
10. Bennett D.W., and Drury A.N. Further observations relating to the physiological activity of adenine compounds. J. Physiology 72 (1931) 288-320
11. Bennett J.P., Cockroft S., and Gomperts B.D. Rat mast cells permeabilized with ATP secrete histamine in response to calcium ions buffered in the micromolar range. J. Physiology 317 (1981) 335-345
12. Berne R.M. Cardiac nucleotides in hypoxia: Possible role in regulation of coronary flow. Am. J. Physiology 204 (1963) 317-322
13. 3H]α, β-methylene ATP binding sites in blood vessels. J. Vascular Res. 30 (1993) 87-101
14. 1 adenosine receptor antagonist: An anatomical and behavioural study. Neuroscience 48 (1992) 807-812
15. 3H]NECA in rat striatal membranes. Molec. Pharmacology 29 (1986) 331-346
16. Bulloch J.M., and McGrath J.C. Blockade of vasopressor and vas deferens responses by α,β-methylene ATP in the pithed rat. Brit. J. Pharmacology 94 (1988) 103-108
17. Burnstock G. Purinergic nerves. Pharmacol. Rev. 24 (1972) 509-560
18. Burnstock G. Do some cells release more than one transmitter?. Neuroscience 1 (1976) 239-248
19. Burnstock G. A basis for distinguishing two types of purinergic receptor. In: Straub R.W., and Bolis L. (Eds). Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach (1978), Raven Press, New York 107-119
20. Burnstock G. Pathophysiology of migraine: A new hypothesis. Lancet i (1981) 1397-1399
21. Burnstock G. Vascular control by purines with emphasis on the coronary circulation. Eur. Heart J. 10 suppl. F (1989) 15-21
22. Burnstock G. Cotransmission. The Fifth Heymans Lecture-Ghent, February 17, 1990. Arch. Internat. Pharmacodyn. Therap. 304 (1990) 7-33
23. Burnstock G. Physiological and pathophysiological roles of purines: An update. Drug Dev. Res. 28 (1993) 195-206
24. Burnstock G., and Buckley N.J. The classification of receptors for adenosine and adenine nucleotides. In: Paton D.M. (Ed). Methods Used in Adenosine Research (Methods in Pharmacology Series) (1985), Plenum Publishing Corp., New York 193-212
25. 2-purinoceptor. Gen. Pharmacology 16 (1985) 433-440
26. Burnstock G., and Warland J.J.I. A pahrmacological study of the rabbit saphenous artery in vitro: A vessel with a large purinergic contractile response to sympathetic nerve stimulation. Br. J. Pharmac. 90 (1987) 110-120
27. 2X-purinoceptor. Brit. J. Pharmac. 90 (1987) 383-391
28. Burnstock G., Campbell G., Satchell D.G., and Smythe A. Evidence that ATP or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory nerve in the gut. Br. J. Pharmac. 40 (1970) 668-688
29. Burnstock G., Dumsday B., and Smythe A. Atropine-resistant excitation of the urinary bladder: The possibility of transmission via nerve releasing a purine nucleotide. Br. J. Pharmac. 44 (1972) 451-461
30. Burnstock G., Crowe R., and Wong H. Comparative and histochemical evidence for purinergic inhibitory innervation of the portal vein of the rabbit, but not guinea-pig. Br. J. Pharmac. 65 (1979) 377-388
31. Cameron D.J. Inhibition of macrophage mediated cytotoxicity by exogenous adenosine 5′-triphosphate. J. Clin. Lab. Immun. 15 (1984) 215-218
32. Chaudry I.H. Use of ATP following shock and ischemia. Ann. N.Y. Acad. Sci. 603 (1990) 130-141
33. Chern Y., Kingk K., Lai H.-L., and Lai H.-T. Molecular cloning of a novel adenosine receptor gene from rat brain. Biochem. Biophys. Res. Commun. 185 (1992) 304-309
34. Cockroft S., and Gomperts B.D. Activation and inhibition of calcium-dependent histamine secretion by ATP ions applied to rat mast cells. J. Physiol. 296 (1979) 243-296
35. Cockroft S., and Gomperts B.D. ATP induces nucleotide permeability in rat mast cells. Nature 279 (1979) 541-542
36. 4- receptor of rat mast cells. Biochem. J. 188 (1980) 789-798
37. Cooper D.M.F., and Londos C. Receptor Biochemistry and Methodology Vol. II (1988), Adenosine Receptors Alan R. Liss, New York
38. 3H]CV1808) labels a novel adenosine receptor in rat brain. J. Pharmacol. Exptl. Therap. 263 (1992) 552-561
39. Daly J.W., Butts-Lamb P., and Padgett W. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines. Cell. Mol. Neurobiol. 3 (1983) 69-80
40. 2 adenosine receptors in spinal mechanisms of antinociception. Eur. J. Pharmac. 139 (1987) 215-223
41. De Mey J.G., and Vanhoutte P.M. Role of the intima in cholinergic and purinergic relaxation of isolated canine femoral arteries. J. Physiol. 316 (1981) 347-355
42. De Mey J.G., Claeys M., and Vanhoutte P.M. Endothelium-dependent inhibitory effects of acetylcholine, adenosine triphosphate, thrombin and arachidonic acid in the canine femoral artery. J. Pharmac. Exptl. Therap. 222 (1982) 166-173
43. De Souza L., Raha S., Lange A., and Reed J.K. Nucleotide receptors in pheochromocytoma (PC12) cells. Soc. Neurosci. Abstr. 18 (1992) 420.1
44. Deuticke H.J. Über der Einfluss von Adenosin und Adenosinphosphorsäuren auf den isolierten Meerschweinchenuterus. Pflüg. Arch. 230 (1932) 537-555
45. Di Virgillo F., Pizzo P., Zanovello P., Bronte V., and Collavo D. Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Immun. Today 11 (1990) 274-277
46. Diamond I., and Gordon A. Use of adenosine agonists and antagonists in the treatment of alcohol abuse. Eur. Patent Appl. O 431 (1991) 758 A2
47. Doi T., Kuzuma S., and Maki Y. Spinal antinociception effects of adenosine in mice. Eur. J. Pharmac. 137 (1987) 227-231
48. Dragunow M. Adenosine receptor antagonism accounts for the seizure-prolonging effects of aminophylline. Pharmac. Biochem. Behav. 36 (1990) 751-755
49. Dragunow M., Goddard G.V., and Laverty R. Is adenosine an endogenous anticonvulsant?. Epilepsia 26 (1985) 480-487
50. Drury A.N., and Szent-Györgyi A. The physiological activity of adenine compounds with special reference to their action upon mammalian heart. J. Physiology 68 (1929) 213-237
51. 1 receptor antagonist reflecting a new binding mode to the receptor. Abst. Soc. Neurosci. 18 (1992) 998
52. 2-purinoceptor antagonist in the mouse vas deferens. Br. J. Pharmac. 93 (1988) 243-245
53. Dunwiddie T.V., and Worth T. Sedative and anticonvulsant effects of adenosine in the mouse and in the rat. J. Pharmacol. Exptl. Therap. 220 (1982) 70-76
54. Edwards F.A., Gibb A.J., and Colquhoun D. ATP receptor-mediated synaptic currents in the central nervous system. Nature 359 (1992) 144-146
55. Edwards F.A., and Gibb A.J. ATP-a fast neurotransmitter. FEBS Lett. 325 (1993) 86-89
56. 1-adenosine antagonist drugs activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. USA 89 (1992) 5562-5566
57. Eikens E., and Wilcken D.E.L. The effect of dipyridamole and of aminophylline on responses to sixty-second coronary artery occlusion in dogs. Austral. J. Exptl. Biol. Med. Sci. 51 (1973) 631-642
58. Evans M.C., Swan J.C., and Meldrum B.S. An adenosine analogue, 2-chloroadenosine, protects against long-term development of ischemic loss in the rat hippocampus. Neurosci. Lett. 83 (1987) 287-292
59. Evans R.J., Derkach V., and Surprenant A. ATP mediates fast synaptic transmission in mammalian neurones. Nature 357 (1992) 503-505
60. Evans R.J., and Surprenant A. Vasoconstriction of guinea-pig submucosal arterioles following sympathetic nerve stimulation is mediated by the release of ATP. Brit. J. Pharmac. 106 (1992) 242-249
61. 2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. J. Clin. Invest. 89 (1992) 191-196
62. 2 dopamine receptors in rat striatum. Mol. Brain Res. 14 (1992) 186-195
63. Fleetwood G., and Gordon J.L. Purinoceptors in the rat heart. Br. J. Pharmac. 90 (1987) 219-227
64. 4-tetraphosphate are present and releasable, but metabolically inactive, in human platelets. Biochem. J. 208 (1982) 737-742
65. Foresta C., Rossato M., and Di Virgilio F. Extracellular ATP is a trigger for the acrosome reaction in human spermatozoa. J. Biol. Chem. 267 (1992) 1-5
66. Forrester T., and Lind A.R. Adenosine triphosphate in the venous effluent and its relationship to exercise. Fed. Proc. 28 (1969) 1280-1283
67. Forrester T., Harper A.M., MacKenzie E.T., and Thomson E.M. Effect of adenosine triphosphate and some derivatives on cerebral blood flow and metabolism. J. Physiol. 296 (1979) 343-355
68. Fukuda J., Fujita Y., and Ohsawa K. ATP content in isolated mammalian nerve cells assayed by a modified luciferin-luciferase method. J. Neurosci. Meth. 8 (1983) 295-302
69. 2 receptor. Mol. Brain Res. 15 (1992) 62-66
70. 2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug Dev. Res. 28 (1993) 374-380
71. Fyffe R.E.W., and Perl E.R. Is ATP a central synaptic mediator for certain primary afferent fibres from mammalian skin?. Proc. Natl. Acad. Sci. USA 81 (1984) 6890-6893
72. Gaddum J.H., and Holtz P. The localization of the action of drugs on the pulmonary vessels of dogs and cats. J. Physiol. 77 (1933) 139-158
73. Gerwins P., and Fredholm B.B. ATP and its metabolite adenosine act synergistically to mobilize intracellular calcium via the formation of inositol 1,4,5-triphosphate in a smooth muscl cell line. J. Biol. Chem. 267 (1992) 16081-16087
74. Giles R.W., and Wilcken D.E.L. Reactive hyperaemia in the dog heart: Interactions between adenosine, ATP and aminophylline and the effect of indomethacin. Cardiovas. Res. 11 (1977) 113-121
75. Gillespie J.H. The biological significance of the linkages in adenosine triphosphoric acid. J. Physiol. 80 (1933) 345-359
76. Gordon J.L. Extracellular ATP: Effects, sources and fate. Biochem. J. 233 (1986) 309-319
77. 86Rb efflux from isolated endothelial cells. Br. J. Pharmac. 76 (1983) 531-541
78. Green P.G., Basbaum A.I., Helms C., and Levine J.D. Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat. Proc. Natl. Acad. Sci. USA 88 (1991) 4162-4165
79. Gustafsson L.E., Wiklund C.U., Wiklund N.P., and Stelius L. Subclassification of neuronal adenosine receptors. In: Jacobson K.A., Daly J.W., and Manganiello V. (Eds). Purines in Cellular Signaling. Targets for Future Drugs (1990), Springer Verlag, New York 200-205
80. Hardebo J.E., and Edvinsson L. Adenine compounds, cerebrovascular effects in vitro with reference to their possible involvement in migraine. Stroke 10 (1979) 58-61
81. Harms L., Finta E.P., Tschöpl M., and Illes P. Depolarization of rat locus coeruleus neurons by adenosine 5′-triphosphate. Neurosci. 48 (1992) 941-952
82. Harrison M.J., Brossmer R., and Goody R.S. Inhibition of platelet aggregation and the platelet release reaction by α,ω diadenosine polyphosphates. FEBS Lett. 54 (1975) 57-60
83. Haslam R.J., and Rosson G.M. Effects of adenosine on levels of adenosine cyclic 3′,5′-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Mol. Pharmac. 11 (1975) 528-544
84. Heffner T.G., Wiley J.N., Williams A.E., Bruns R.F., Coughenour L.L., and Downs D.A. Comparison of the behavioural effects of adenosine agonists and dopamine antagonists in mice. Psychopharmac. 98 (1989) 31-37
85. 6-phenylisopropyladenosine. J. Pharm. Pharmacol. 35 (1983) 679-680
86. Holton P. The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J. Physiol. 145 (1959) 494-504
87. Holton F.A., and Holton P. The possibility that ATP is a transmitter at sensory nerve endings. J. Physiol. 119 (1953) 50-51P
88. Holton F.A., and Holton P. The capillary dilator substance in dry powders of spinal roots: A possible role of adenosine triphosphate in chemical transmission from nerve endings. J. Physiol. 126 (1954) 124-140
89. Holton P., and Perry W.L.M. On the transmitter responsible for antidromic vasodilatation in the rabbits ear. J. Physiol. 114 (1951) 240-251
90. Honey R.M., Ritchie W.T., and Thompson W.A.R. The action of adenosine on the human heart. Quart. J. Med. 23 (1930) 485-490
91. 2 purinergic receptors and cellular calcium metabolism in A431 human epidermoid carcinoma cells. Am. J. Physiol. 262 (1992) C635-C643
92. 2-purinergic receptor subtypes of endothelium and smooth muscle in canine blood vessels. J. Pharmac. Exptl. Therap. 241 (1987) 501-506
93. Hoyle C.H.V. Pharmacological activity of adenine dinucleotides in the periphery: Possible receptor classes and transmitter function?. Gen. Pharmac. 21 (1990) 827-831
94. Hoyle C.H.V. Transmission: purines. In: Burnstock G., and Hoyle C.H.V. (Eds). The Autonomic Nervous System, Vol. I: Autonomic Neuroeffector Mechanisms (1992), Harwood Academic Publishers, Switzerland 367-407
95. Hoyle C.H.V., and Burnstock G. ATP receptors and their physiological roles. In: Stone T.W. (Ed). Adenosine in the Nervous System (1991), Academic Press Ltd., London 43-76
96. Hoyle C.H.V., and Burnstock G. Purinergic receptors. In: van Meel J.C.A., and Doods H.N. (Eds). Receptor Data for Biological Experiments: A Guide to Drug Selectivity (1991), Ellis Horwood, Chichester 54-61
97. Hoyle C.H.V., and Burnstock G. Postganglionic efferent transmission in the bladder and urethra. In: Maggi C.A. (Ed). Nervous Control of the Urogenital System (1993), Harwood Academic Publishers, Switzerland 349-381
98. 2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli. Br. J. Pharmac. 99 (1990) 617-621
99. Hudlicka O. Development of microcirculation: Capillary growth and adaptation. Handbook of Physiology: The Cardiovascular System IV (1984), American Physiological Society, Bethesda MD 165-216
100. Ishikawa S. Actions of ATP and α,β-methylene ATP on the neuromuscular transmission and smooth muscle membrane of the rabbit and guinea-pig mesenteric arteries. Br. J. Pharmacol. 86 (1985) 777-787
101. Jacobsen E.J., and McCall J.M. Acute ischemic and traumatic injury to the CNS. Ann. Rep. Med. Chem. 25 (1990) 31-40
102. Jacobson K.A., van Galen P.J.M., and Williams M. Adenosine receptors: Pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem. 35 (1992) 407-422
103. 2 adenosine receptors. Drug Dev. Res. 28 (1993) 226-231
104. James S., and Richardson P.J. Production of adenosine from extracellular ATP at the striatal cholinergic synapse. J. Neurochem. 60 (1993) 219-227
105. 2 purinoceptors in the isolated rabbit central ear artery. Blood Vess. 22 (1985) 145-155
106. 2-purinoceptors mediate both vasodilatation (via the endothelium) and vasoconstriction of the isolated rat femoral artery. Eur. J. Pharmacol. 107 (1985) 161-168
107. Keppens S., Vandekerckhove A., and de Wulf H. Extracellular ATP and UTP exert similar effects on rat isolated hepatocytes. Br. J. Pharmac. 105 (1992) 475-479
108. Kogure K., and Olonso O.F. A pictorial representation of endogenous brain ATP by a bioluminescent method. Brain Res. 154 (1978) 273-284
109. Krishtal O.A., Marchenko S.M., and Pidoplichko V.I. Receptor for ATP in the sensory neurons of rats. Neurosci. Lett. 35 (1983) 41-45
110. 2-generation. Lab. Invest. 58 (1988) 448-453
111. Kuroda Y., and Kobayashi K. Increase in cyclic AMP levels by adenosine derivatives in mammalian brain synaptosomes. Proc. Japn. Acad. 54 B (1975) 243-247
112. Küpferman I. Functional studies of cotransmission. Physiol. Rev. 71 (1991) 683-711
113. Lee K.S., Schubert P., Emmert H., and Kreutzberg G.W. Effects of adenosine versus adenine nucleotides on evoked potentials in a rat hippocampal slice preparation. Neurosc. Lett. 23 (1981) 309-314
114. 2X-purinoceptors in the rabbit isolated ear artery. Br. J. Pharmacol. 101 (1990) 645-649
115. Libert F., Parmentier M., Lefort A., Dinsart C., Van-Sande J., Maenhaut C., Simons M.J., Dumont J.E., and Vassart G. Selective amplifiction and cloning of four new members of the G-protein-coupled receptor family. Science 244 (1989) 569-572
116. 1 adenosine receptor. EMBO J. 10 (1991) 1677-1682
117. 1 adenosine receptor. Biochem. Biophys. Res. Commun. 187 (1992) 919-926
118. Lidner F., and Rigler R. Über die Beeinflussung der Weite der Herzkranzgefässe durch Produkte des Zelkernstoffwechsels. Pflüg. Arch. 226 (1930) 697-708
119. Linden J., Tucker A.L., Robeva A.S., Graber S.G., and Munshi R. Properties of recombinant adenosine receptors. Drug Dev. Res. 28 (1993) 232-236
120. Londos C., Cooper D.M.F., and Wolff J. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA 77 (1980) 2551-2554
121. Londos C., and Wolff J. Two distinct adenosine-sensitive sites on adenylate cyclase. Proc. Natl. Acad. Sci. USA 74 (1977) 5482-5486
122. Lustig K.D., Shiau A.K., Brake A.J., and Julius D. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc. Natl. Acad. Sci. USA 90 (1993) 5113-5117
123. 3A) in human platelets. Biochem. Biophys. Res. Commun. 115 (1983) 253-260
124. Macfarlane D.E., and Mills D.C. The effects of ATP on platelets: Evidence against the central role of released ADP in primary aggregation. Blood 46 (1975) 309-320
125. 2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Commun. 173 (1990) 1169-1178
126. 1 adenosine receptor from rat brain. Mol. Pharmacol. 40 (1991) 1-7
127. Marangos P.J. Potential therapeutic roles for adenosine in neurologic disease. In: Stone T.W. (Ed). Adenosine in the Nervous System (1991), Academic Press, London 217-265
128. Marangos P.J., and Boulenger J.P. Basic and clinical aspects of adenosinergic neuromodulation. Neurosci. Biobehav. Rev. 9 (1985) 421-430
129. 2-purinoceptor mediates endothelium-dependent relaxation of the pig aorta. Eur. J. Pharmacol. 108 (1985) 295-299
130. Mathieson J.J.I., and Burnstock G. Purine-mediated relaxation and constriction of isolated rabbit mesenteric artery are not endothelium-dependent. Eur. J. Pharmacol. 118 (1985) 221-229
131. Meghji P. Storage, release, uptake, and inactivation of purines. Drug Dev. Res. 28 (1993) 214-219
132. Mills D.C.B., Robb I.A., and Roberts G.C.K. The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets during aggregation. J. Physiol. 195 (1968) 715-729
133. Muramatsu I., and Kigoshi S. Purinergic and non-purinergic innervation in the cerebral arteries of the dog. Br. J. Pharmacol. 92 (1987) 901-908
134. Nees S., and Gerlach E. Adenine nucleotide and adenosine metabolism in cultured coronary endothelial cells: Formation and release of adenine compounds and possible functional implications. In: Berne R.M., Rall T.W., and Rubio R. (Eds). Regulatory Functions of Adenosine (1983), Martinus Nijhoff, The Hague 347-360
135. Nehlig A., Daval J.L., and Debry G. Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev. 17 (1992) 139-170
136. Newby A.C. Adenosine and the concept of "retaliatory metabolites". Trends Biochm. Sci. 9 (1984) 42-44
137. O'Connor S.E., Dainty I.A., and Leff P. Further subclassification of ATP receptors based on agonist studies. Trends Pharmac. Sci. 12 (1991) 137-141
138. Okada Y., and Kuroda Y. Inhibitory action of adenosine and adenine nucleotides on the postsynaptic potential of olfactory cortex slices of the guinea pig. Proc. Japn. Acad. 51 (1975) 491-494
139. Okada Y., and Kuroda Y. Inhibitory actions of adenosine and adenosine analogues on neurotransmission in the olfactory cortex slice of guinea pig-structure-activity relationships. Eur. J. Pharmacol. 61 (1980) 137-146
140. 1 adenosine receptor. J. Biol. Chem. 267 (1992) 10764-10770
141. Olsson R.A., Snow J.A., and Gentry M.K. Adenosine metabolism in canine myocardial reactive hypertension. Circ. Res. 42 (1978) 358-362
142. Olsson R.A., and Pearson J.D. Cardiovascular purinoceptors. Physiol. Rev. 70 (1990) 761-845
143. Ostern P., and Parnas J.K. Über die Auswertung von Adenosinderivaten am überlebenden Froscherz. Biochem Zeitsherift 248 (1932) 389-397
144. Paddle B.M., and Burnstock G. Release of ATP from perfused heart during coronary vasodilatation. Blood Vessels 11 (1974) 110-119
145. Palea S., Artibani W., Ostardo E., Trist D.G., and Pietra C. Evidence for purinergic neuro-transmission in human urinary bladder affected by interstitial cystitis. J. Urol. 150 (1993) 2007-2012
146. Palmer R.M.J., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 316 (1987) 724-725
147. Pantely G.A., and Bristow J.D. Adenosine. Renewed interest in an old drug. Circulation 82 (1990) 1854-1856
148. Pearson J.D., and Gordon J.L. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature 281 (1979) 384-386
149. Phillis J.W., Edstrom J.P., Kostoploulos G.K., and Kirkpatrick J.R. Effects of adenosine and adenine nucleotides on synaptic transmission in the cerebral cortex. Can. J. Physiol. Pharmacol. 57 (1979) 1289-1312
150. 2b receptor from human brain. Biochem. Biophys. Res. Commun. 187 (1992) 86-93
151. Potter P., and White T.D. Release of adenosine 5′-triphosphate from synaptosomes from different regions of rat brain. Neuroscience 5 (1980) 1351-1356
152. Priebe T., Platzoncas C.D., and Nelson J.A. Adenosine receptors and modulation of natural killer cell activity by purine nucleosides. Cancer Res. 50 (1992) 4328-4331
153. 6-(L-Phenylisopropyl)adenosine (L-PIA) increases slow-wave sleep (S2) and decreases wakefulness in rats. Brain Res. 246 (1982) 178-180
154. Rapaport E. Anticancer activities of adenine nucleotides in tumour bearing hosts. Drug Dev. Res. 28 (1993) 428-431
155. Rapaport E., and Fontaine J. Anticancer activities of adneine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc. Natl. Acad. Sci. USA 86 (1989) 1662-1666
156. Rathbone M.P., Deforge S., Deluca D., Gabel B., Laurenssen C., Middlemiss P., and Parkinson S. Purinergic stimulation of cell division and differentiation mechanisms and pharmacological implications. Medical Hypotheses 37 (1992) 213-219
157. Regenold J.T., and Illes P. Inhibitory adenosine A1-receptors on rat locus coeruleus neurons. An intracellular electrophysiological study. Naunyn Schmiedeberg's Arch. Pharmacol. 341 (1990) 225-231
158. 2-purinoceptors: Supporting evidence for purinergic innervation of the rabbit portal vein. Eur. J. Pharmacol. 140 (1987) 47-53
159. 1-adenosine receptor that is widely expressed in brain and spinal cord. Mol. Endocrinol. 5 (1991) 1037-1048
160. 3) adenosine receptor. Progr. Neurobiol. 26 (1986) 179-209
161. 2b-adenosine receptor. Mol. Endocrinol. 5 (1992) 1037-1048
162. Rudolphi K.A., Schubert P., Parkinson F.E., and Fredholm B.B. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 13 (1992) 439-445
163. Salt T.E., and Hill R.G. Excitation of single sensory neurones in the rat caudal trigeminal nucleus by iontophoretically applied adenosine 5′-triphosphate. Neurosci. Lett. 35 (1983) 53-57
164. Salter M.W., De Koninck Y., and Henry J.L. Physiological roles for adenosine and ATP in synaptic transmission in the spinal dorsal horn. Prog. Neurobiol. 41 (1993) 125-156
165. Salvatore C.A., Luneau C.J., Johnson R.G., and Jacobson M.A. Molecular cloning and characterization of human A1 and A2 adenosine receptors. Int. J. Purine Pyrim. Res. 3 (1992) 82
166. Sarges R., Howard H.R., Browne R.G., Lebel L.A., Seymour P.A., and Koe B.K. 4-Amino-[1,2,4]triazolo[4,3a]-quinoxalines. A novel class of potent adenosine antagonists and potential rapid-onset antidepressants. J. Med. Chem. 33 (1990) 2240-2254
167. Sattin A., and Rall T.W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′,5′-phosphate content of guinea-pig cerebral slices. Mol. Pharmacol. 6 (1970) 13-23
168. Sawynok J., Downie J.W., Reid A.R., Cahill C., and White T.D. ATP release from dorsal spinal cord synaptosomes: Characterization and neuronal origin. Brain Res. 610 (1993) 32-38
169. 1-antagonists for treatment of cognitive deficits. Nucleos. Nucleot. 10 (1991) 1067-1076
170. 2X receptors in the pithed rat. J. Autonomic Pharmacol. 9 (1989) 371-380
171. Schmidt A., Ortaldo J.R., and Herberman R.B. Inhibition of human natural killer cell reactivity by exogenous adenosine 5′-triphosphate. J. Immunol. 132 (1984) 146-150
172. Schubert P., Komp W., and Kreutzberg G.W. Correlation of 5′-nucleotidase activity and selective transneuronal transfer of adenosine in the hippocampus. Brain Res. 168 (1979) 419-424
173. Sebastiâo A.M., and Ribeiro J.A. On the adenosine receptor and adenosine inactivation at the rat diaphragm neuromuscular junction. Br. J. Pharmacol. 94 (1988) 109-120
174. Sebastiâo A.M., and Ribeiro J.A. 1,3,8- and 1,3,7-substituted xanthines: Relative potency as adenosine receptor antagonists at the frog neuromuscular junction. Br. J. Pharmacol. 96 (1989) 211-219
175. Shimada S.G., and Stitt J.T. An analysis of the purinergic component of active muscle vasodilation obtained by stimulation of the hypothalamus in rabbits. Br. J. Pharmacol. 83 (1984) 577-589
176. Shinozuka K., Bjür R., and Westfall D.P. Characterization of prejunctional purinoceptors on adrenergic nerves of the rat caudal artery. Naunyn Schmiedeberg's Arch. Pharmacol. 338 (1988) 221-227
177. Silinsky E.M., Gerzanich V., and Vanner S.M. ATP mediates excitatory synaptic transmission in mammalian neurones. Br. J. Pharmacol. 106 (1992) 762-763
178. Sollevi A., Lagerkranser M., Irestedt L., Gordon E., and Lindqvist C. Controlled hypotension with adenosine in cerebral aneurism surgery. Anesthesiology 61 (1984) 400-405
179. 2-adenosine receptor. Mol. Endocr. 6 (1992) 384-393
180. Stone T.W. Physiological roles for adenosine and adenosine 5′-triphosphate in the nervous system. Neuroscience 6 (1981) 523-555
181. In: Stone T.W. (Ed). Adenosine in the Nervous System (1991), Academic Press, London
182. 2-purinoceptors in hippocampal pathways. Br. J. Pharmacol. 97 (1989) 631-635
183. - channels in normal and cystic fibrosis airway epithelial cells by extracellular ATP. Proc. Natl. Acad. Sci. USA 89 (1992) 1621-1625
184. 2 antagonist. Intl. J. Purine Pyrim. Res. 3 (1992) 107
185. + release purine from capsaicin-sensitive primary afferent nerve terminals in the spinal cord. J. Pharmac. Exptl. Therap. 248 (1989) 447-454
186. Takahashi Y., Ishii N., Lue T.F., and Tanagho E.A. Effects of adenosine on canine penile erection. J. Urol. 148 (1992) 1323-1325
187. Tarasova O.S., and Rodionov I.M. The role of purinergic neurotransmission in various cardiovascular reflexes. Acta Physiol. Scand. 146 (1992) 441-448
188. Toda N., Okunishi H., Taniyama K., and Miyazaki M. Responses to adenine nucleotides and related compounds in isolated dog cerebral, coronary and mesenteric arteries. Blood Vessels 19 (1982) 226-236
189. 1 adenosine receptor cDNA. Mol. Brain Res. 16 (1992) 365-370
190. Tschöpl M., Harms L., Nörenberg W., and Illes P. Excitatory effects of adenosine 5′-triphosphate on rat locus coeruleus neurones. Eur. J. Pharmacol. 213 (1992) 71-77
191. 1 receptor cDNA. FEBS Lett. 297 (1992) 107-111
192. Van Calker D., Müller M., and Hampbrecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33 (1979) 999-1005
193. Vapaatalo H., Onken D., Neuvonen P.J., and Westermann E. Stereospecificity in some central and circulatory effects of phenylisopropyl-adenosine (PIA). Arzneim. Forsch. 25 (1975) 407-410
194. 2X receptor, in rabbit basilar artery: A receptor for pyrimidine nucleotides and a receptor for purine nucleotides. Naunyn Schmiedeberg's Arch. Pharmac. 341 (1990) 538-546
195. Voogd T.E., Vansterkenburg L.M., Wilting J., and Janssen L.H.M. Recent research on the biological activity of suramin. Pharmac. Rev. 45 (1993) 177-203
196. Wauquier A., Van Belle H., Van den Broek W.A.E., and Janssen P.A.J. Sleep improvement in dogs after oral administration of mioflazine, a nucleoside transport inhibitor. Psychopharmacol. 91 (1987) 434-439
197. Webb T.E., Simon J., Krishek B.J., Bateson A.N., Smart T.G., King B.F., Burnstock G., and Barnard E.A. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett. 324 (1993) 219-225
198. Wedd A.M. The action of adenosine and certain related compounds on the coronary flow of the perfused heart of the rabbit. J. Pharmac. Therap. 41 (1931) 355-366
199. + and by veratridine. J. Neurochem. 30 (1978) 329-336
200. White T.D. Role of adenine compounds in autonomic neurotransmission. In: Bell C. (Ed). Pharmacology and Therapeutics Vol. 38 (1988), Pergamon Press, London 129-168
201. White T.D., Potter P., and Wonnacott S. Depolarisation-induced release of ATP from cortical synaptosomes is not associated with acetylcholine release. J. Neurochem. 34 (1980) 1109-1112
202. + and veratridine-induced release of ATP from synaptosomes prepared from the myenteric plexus of the guinea-pig small intestine. J. Neurochem. 40 (1985) 1069-1075
203. 2-purinocpetor subtypes in guinea-pig smooth muscle. Eur. J. Pharmac. 148 (1988) 361-370
204. Williams M. Purinergic receptors as potential drug targets. Drug News Persp. 4 (1991) 5-12
205. Williams M. Purinergic drugs: Opportunities in the 1990s. Drug Dev. Res. 28 (1993) 438-444
206. Yarborough G.G., and McGuffin-Clineschmidt J.C. In vivo behavioural assessment of central nervous system purinergic receptors. Eur. J. Pharmac. 76 (1981) 137-144
207. Zheng L.M., Zychlinsky A., Liu C.-C., Ojcius D.M., and Ding-E Young J. Extracellular ATP as a trigger for apoptosis or programmed cell death. J. Cell Biol. 112 (1991) 279-288
208. 3 adenosine receptor. Proc. Natl. Acad. Sci. USA 89 (1992) 7432-7436